Form 8-K - Current report:
SEC Accession No. 0001683168-24-005070
Filing Date
2024-07-26
Accepted
2024-07-26 08:00:11
Documents
17
Period of Report
2024-07-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 37511
2 SALES AGREEMENT cns_ex0101.htm EX-1.1 273055
3 ARENTFOX SCHIFF LLP LEGAL OPINION cns_ex0501.htm EX-5.1 14988
4 FORM OF WAIVER AND CONSENT cns_ex1001.htm EX-10.1 19753
8 GRAPHIC image_001.jpg GRAPHIC 6363
  Complete submission text file 0001683168-24-005070.txt   604195

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cnsp-20240726.xsd EX-101.SCH 3018
6 XBRL LABEL FILE cnsp-20240726_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE cnsp-20240726_pre.xml EX-101.PRE 22361
19 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3802
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 241143577
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)